Stock-Based Compensation

3 Months Ended

Apr. 30, 2016

5. Stock-Based Compensation

The compensation costs that have been charged against income for the thirteen weeks ended April 30, 2016 and May 2, 2015 were as follows (in thousands):

	Thirteen Weeks Ended
	April 30, 2016		May 2, 2015
Stock-based compensation expense by type:
Stock options	$	381	$	340
Restricted stock unit awards, including performance-based		1,709		2,278
Employee stock purchases		36		37
Director deferred compensation		23		18
Total stock-based compensation expense		2,149		2,673
Income tax benefit recognized		781		985
Stock-based compensation expense, net of income tax	$	1,368	$	1,688

In the thirteen weeks ended April 30, 2016 and May 2, 2015, we granted the following equity awards:

	Thirteen Weeks Ended
	April 30, 2016		May 2, 2015
Stock options		36,041		19,090
Restricted stock unit awards		100,775		69,529
Performance-based restricted stock unit awards		45,300		29,300
Deferred stock units		13,482		11,252

At April 30, 2016, the total compensation costs, related to nonvested restricted stock unit awards not yet recognized was $10.9 million and the weighted-average period over which such awards are expected to be recognized was 2.8 years. There are no future compensation costs related to nonvested stock options to be recognized at April 30, 2016.

Under the 2012 Non-Employee Director Equity Plan (2012 Plan), a total of 2,851 and 1,981 shares of our common stock were awarded during the thirteen weeks ended April 30, 2016 and May 2, 2015, respectively, as part of the annual equity award to directors in the first quarter. The weighted-average grant date fair value of stock options granted during the thirteen weeks ended April 30, 2016 and May 2, 2015 was $10.56 and $17.82 per share, respectively.

Our employee purchases of common stock, the average price per share and the weighted-average grant date fair value of shares purchased through the our employee stock purchase plan were as follow:

	Thirteen Weeks Ended
	April 30, 2016		May 2, 2015
Shares purchased		5,617		3,449
Average price per share	$	25.70	$	41.17
Weighted average fair value at grant date	$	6.47	$	10.72